Naratriptan Hydrochloride

Sold as Amerge. Every FDA application for this active ingredient: 1 branded and 9 generic.

As of Nov 15, 2026, FDA lists 10 applications for Naratriptan Hydrochloride (sold as Amerge), first approved Feb 10, 1998, with 0 new uses approved and 0 published complete response letters.

First approved: Feb 10, 1998
Applications: 10
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.3M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Naratriptan HCl	Part D	$3.3M	+12%	24,438

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

NARATRIPTAN HCL 1 MG TABLET: $1.72 per unitGeneric · -1% in a year
NARATRIPTAN HCL 2.5 MG TABLET: $1.10 per unitGeneric · -9% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Feb 10, 1998	AmergeNDA 20763 · New molecular entity	Glaxosmithkline LLC	10	Discontinued
Jul 7, 2010	NaratriptanANDA 78751	Ani Pharms	3	Discontinued
Jul 7, 2010	NaratriptanANDA 90288	Chartwell Rx	2	Discontinued
Jul 7, 2010	NaratriptanANDA 90381	Hikma	3	Marketed
Jul 8, 2010	NaratriptanANDA 91326	Padagis US	2	Discontinued
Feb 14, 2011	NaratriptanANDA 91552	Sun Pharm Inds Ltd	2	Discontinued
Feb 28, 2011	NaratriptanANDA 200502	Heritage	3	Marketed
Apr 22, 2011	NaratriptanANDA 91373	Apotex Corp	2	Discontinued
Apr 30, 2012	NaratriptanANDA 91441	Orbion Pharms	3	Marketed
May 31, 2012	NaratriptanANDA 202431	Aurobindo Pharma USA	2	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA